Evidence map›Paper›PMID 35839476›Full record

ArticleAmerican journal of respiratory and critical care medicine2022

SARS-CoV2 Endotheliopathy: Insights from Single Cell RNAseq.

Mst Shamima Khatun, Xuebin Qin, Derek A Pociask, Jay K Kolls

Abstract readLetterComment
In one paragraph

Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Mst Shamima KhatunTulane University School of Medicine New Orleans, Louisiana.
Xuebin QinTulane University School of Medicine New Orleans, Louisiana.
Derek A PociaskTulane University School of Medicine New Orleans, Louisiana.
Jay K KollsTulane University School of Medicine New Orleans, Louisiana.

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Tulane University COVID Antibody and Immunity Network (TUCAIN) SupplementU54CA260581 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI ROBINSON, JAMES E · 2020 to 2024
$9.2M
Training in CD4 T-cell Lung ImmunityR35HL139930 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2018 to 2024
$6.3M
Role of Complement Activation in Severe COVID-19R01HL165265 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2022 to 2025
$2.9M
Generation and Characterization of a Novel Cell Subpopulation Ablation ModelR21OD024931 · OD · TULANE UNIVERSITY OF LOUISIANA · PI QIN, XUEBIN · 2018 to 2019
$450k
NCI NIH HHS U54 CA260581NHLBI NIH HHS R01 HL165265NHLBI NIH HHS R35 HL139930NIH HHS P51 OD011104NIH HHS R21 OD024931
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsHumansRNA, ViralAntiviral AgentsRNA, Viral

Identifiers

PMID35839476
PMCPMC9704844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.